Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – Sarcoma

3452 - Unravelling omics landscape and targeting oncogenic pathways in undifferentiated pleomorphic sarcomas (UPS)


28 Sep 2019


Poster Discussion – Sarcoma


Maud Toulmonde


Annals of Oncology (2019) 30 (suppl_5): v683-v709. 10.1093/annonc/mdz283


M. Toulmonde1, C. Lucchesi2, S. Verbeke3, A. Crombe4, V. Chaire3, A. Laroche3, F. Le Loarer5, F. Bertucci6, J. Adam7, F. Bertolo2, D. Geneste2, L. Bianchini8, B. Dadone-Montaudie8, T. Hembrough9, F. Cecchi10, F. Giles11, A. Italiano1

Author affiliations

  • 1 Medical Oncology, Institut Bergonié, 33000 - Bordeaux/FR
  • 2 Bioinformatics, Institut Bergonié, 33000 - Bordeaux/FR
  • 3 Inserm U1218, Institut Bergonié, 33000 - Bordeaux/FR
  • 4 Radiology, Institut Bergonié, 33000 - Bordeaux/FR
  • 5 Pathology, Institut Bergonié, 33000 - Bordeaux/FR
  • 6 Crcm, Institut Paoli Calmettes, 13274 - Marseille/FR
  • 7 Pathology, Gustave Roussy, 94800 - Villejuif/FR
  • 8 Ircan, University of Nice-Sophia Antipolis, Nice/FR
  • 9 Oncology, NantOmics, LLC, 20850 - Rockville/US
  • 10 Translational Medicine, NantOmics, LLC, 20850 - Rockville/US
  • 11 Developmental Therapeutics, Epigene Therapeutics, 60611 - Chicago/US


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 3452


UPS are a heterogenous group of poorly differentiated tumors. We hypothesized that there is a link between dedifferentiation state of UPS and immune infiltrate and that this relationship relies on specific pathways activation and related genomics alterations with potential therapeutic impact. Main objectives were to generate a comprehensive Omics landscape of true UPS and test potential targets for therapeutics approach on cell lines and patient tumour derived mouse xenografts (PDX).


We analysed 135 UPS cases, 25 of which were selected for full exome and RNA sequencing, proteomics profiling conducted by data-independent acquisition mass spectrometry, as well as immune profiling by immunohistochemistry (IHC).


Using unsupervised consensus clustering and hierarchical clustering of RNA-sequencing, we identified two main groups of patients: group A and B, with associated gene clusters. Group A was mainly enriched in genes that play a crucial role in both normal development and stemcellness, notably FGFR2. Group B was strongly enriched in genes involved in immunity. Using proteomics analysis we found two main proteomic groups - PA and PB – that highly correlated with the two main genetic groups - A and B. The proteome group PB, associated with the immune-high group B, was significantly enriched in immune response pathways, whereas the proteome group PA, associated with the immune-low group A, was mainly enriched in MYC targets and epithelial mesenchymal transition pathways. We then further assessed the therapeutic potential of this classification by using in vitro and in vivo PDX models directly derived from patient tumor samples from the molecular profiling study. We showed robust anti-tumor activity of FGFR2 inhibitor JNJ-42756493 and of NEO2734, a first-in-class epigenetic modifier that notably inhibits Bromodomain and Extra-Terminal domain (BET) family and Cyclic AMP response element binding protein (CREB)-binding (CBP) proteins, in models from group A, selectively.


This integrated analysis of UPS allowed the identification of two main entities with distinct molecular features, immune phenotypes, as well as differential sensitivity to specific anti-cancer agents.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.


La Ligue.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.